Rosen Law Firm has filed a class action lawsuit on behalf of Ardelyx stock purchasers between January and August 2026. The suit alleges Ardelyx made false and misleading statements about the commercial performance and growth prospects of its drugs XPHOZAH and IBSRELA, particularly regarding payer access and reimbursement barriers that slowed patient starts. Investors who bought Ardelyx stock during this period may be entitled to compensation. Those interested in joining the lawsuit must act by November 16, 2026.
The news concerns Ardelyx, Inc. and a securities fraud lawsuit. For readers following the health sector, here is Pluang's market snapshot as of Sep 21, 2026 21:11 WIB: out of 95 priced US health stocks, 54 rose and 39 fell today. Notable movers include HIMS at USD 28.67 with a 1-day change of +2.43%, ACB at USD 3.96 with +2.33%, and AMPH at USD 24.16 with +2.29%.
Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...
A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandat...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...
Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...
